Bavarian Nordic will not paintings on its immuno-oncology vaccine professionalgram to instead focus on infectious disease R&D, with the compathe big apple’s “document” 2023 gross sales buoyed via its mpox vaccine Jynneos.
The Danish biotech used to be paintingsing on a Segment I will be able tocer vaccine, dubbed TAEK-VAC, which tarwill get a tumor-associated antigen. The asset used to be being investigated in subjects with chordoma (tumor within the backbone or on the base of the cranium) or HER2-positive breast cancer.
Unencumber this text straight away via turning into a loose subscriber.
You’ll get get entry to to loose articles every month, plus you’ll be able to customise what newsletters get delivered on your inbox every week, together with breaking information.
